Intravitreal Dexamethasone Implant for the Treatment of Macular Edema in Chronic Non-infectious Uveitis

Tsang, Adrian; Virgili, Gianni; Abtahi, M; Gottlieb, Chloe

doi:10.3109/09273948.2016.1160130

Cited by 32 publications

(23 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 Another study reported that the improvements in BCVA and central retinal thickness at 1 month were similar (not significantly different) following the first and second implants. 84 In a study of uveitis patients the median time from first to second implant was 10 months 50 whereas in four studies of uveitic macular oedema the mean/median time from first to second implant was 4.7, 81 5.0, 51 7.1 83 and 10 86 months. The mean time from second to third implant was 3.4 months in one study of uveitic macular oedema.…”

Section: Dexamethasone Studiesmentioning

confidence: 99%

“…18,50,51,[79][80][81][82][83][84][85][86] This is based on data from the company submission for DEX; 43 the original study publications have not been examined because of time constraints. These data are included here as they provide some data on repeat implants, implants in both eyes and corticosteroid reduction, which were not assessed in the HURON trial.…”

Section: Dexamethasone Studiesmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Declared competing interests of authors: Fahd Quhill has received personal fees from Allergan for participation in medical education and training, and has participated in advisory boards given his clinical expertise in the role of steroids in diabetic macular oedema. He has also received support from Allergan to attend international conferences.Published November 2017 DOI: 10.3310/hta21680 This report should be referenced as follows: This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 15/64/07. The protocol was agreed in June 2016. The assessment report began editorial review in December 2016 and was accepted for publication in May 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expre...

show abstract

Section: Dexamethasone Studiesmentioning

confidence: 99%

Section: Dexamethasone Studiesmentioning

confidence: 99%

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Squires

Poku

Bermejo

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Intravitreal drugs are now considered as a safe and effective treatment option for the management of noninfectious uveitis, especially in patients with unilateral disease without any systemic component. [ 15 16 ] This article reviews the various intravitreal drugs used for the treatment of ME secondary to noninfectious uveitis.…”

mentioning

confidence: 99%

Intravitreal therapeutic agents in noninfectious uveitic macular edema

Shah

Majumder

Biswas

2018

Indian J Ophthalmol

View full text Add to dashboard Cite

The management of uveitis is challenging for most treating ophthalmologists. The treatment of uveitis often requires the use of high dose of systemic corticosteroid and immunosuppressive agents, which are almost always associated with potential side effects. Intravitreal medications have become a popular mode of drug administration in uveitis patients as they provide high volume of drug to the target tissues, eliminating the risk of systemic toxicity. There has been tremendous development in the intravitreal therapeutics over the last few years. With the advent of sustained-release technique, increasing patient compliance, biodegradable nature of the implant, and introduction of newer agents with better safety profile, the intravitreal medications have become more popular in recent years. This review presents evidence in the scientific literature supporting the use of intravitreal medications for the management of uveitis and its complications.

show abstract

“…Topical DEX has proven efficacious in the management of postoperative inflammation in the anterior segment after cataract surgery, treatment of anterior uveitis (iritis) and dry-eye disease symptoms [3][4][5]. Intravitreal administration of DEX has been effective in the treatment of macular edema following retinal vein occlusion, diabetic macular edema [6][7][8], and non-infectious uveitis [9], particularly when other therapeutic agents have failed to provide treatment benefits. However, DEX has a short halflife [10], and requires multiple applications.…”

mentioning

confidence: 99%

Pentablock Copolymer Dexamethasone Nanoformulations Elevate MYOC: In Vitro liberation, Activity and Safety in Human Trabecular Meshwork Cells

Agrahari

Navarro

et al. 2017

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

Intravitreal Dexamethasone Implant for the Treatment of Macular Edema in Chronic Non-infectious Uveitis

Abstract: The DEX implant is an effective adjunct treatment to systemic corticosteroid or immunomodulatory therapy. Additional research is required to determine the efficacy of DEX implant as monotherapy for controlling chronic uveitic macular edema.

Cited by 32 publications

References 14 publications

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults

Intravitreal therapeutic agents in noninfectious uveitic macular edema

Pentablock Copolymer Dexamethasone Nanoformulations Elevate MYOC: In Vitro liberation, Activity and Safety in Human Trabecular Meshwork Cells

Contact Info

Product

Resources

About